Nektar Therapeutics
(NASDAQ:NKTR)
$0.53
0.04 (7.14%)
Open: 3:37 PM
NKTR Stock Price Graph
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- YTD
- All
NKTR Stock Price Today
Nektar Therapeutics (NKTR) stock rallied over 11.70% intraday to trade at $0.525 a share on NASDAQ. The stock opened with a loss of -0.20% at $0.49 and touched an intraday high of $0.50, rising 7.14% against the last close of $0.49. The Nektar Therapeutics in stock market went to a low of $0.47 during the session.
NKTR Stock Snapshot
$0.49
Prev. Close
100.15 Million
Market Cap
$0.47
Day Low
$0.49
Open
N/A
Number of Shares
$0.50
Day High
N/A
P/E ratio
-1.55
EPS (TTM)
1.95
Cash Flow per Share
N/A
Free Float in %
0.83
Book Value
1128104.00
Volume
NKTR Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|
Contact Details
455 Mission Bay Boulevard SouthSan Francisco, CA 94158US
Website:https://www.nektar.com
Contact #:415 482 5300
Company Information
EmployeesN/A
Beta0.89
Sales or Revenue$88.26 Million
5Y Sales Change37.56%
Fiscal Year EndsDec. 2022
SectorHealthcare
IndustryBiotechnology
About Company
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Peers
Frequently Asked Questions
What is the current Nektar Therapeutics (NKTR) stock price?
Nektar Therapeutics (NASDAQ: NKTR) stock price is $0.53 in the last trading session. During the trading session, NKTR stock reached the peak price of $0.50 while $0.47 was the lowest point it dropped to. The percentage change in NKTR stock occurred in the recent session was 11.70% while the dollar amount for the price change in NKTR stock was $0.06.
NKTR's industry and sector of operation?
The NASDAQ listed NKTR is part of Biotechnology industry that operates in the broader Healthcare sector. Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19.
Who are the executives of NKTR?
Dr. Jonathan Zalevsky Ph.D.
Senior Vice President & Chief R&D Officer
Mr. Howard W. Robin
Chief Executive Officer, Pres & Director
Dr. Kevin Brodbeck Ph.D.
Senior Vice President of Technical Operations
Mr. John P. Northcott
Strategic Consulting Advisor
How NKTR did perform over past 52-week?
NKTR's closing price is 0.32% higher than its 52-week low of $0.45 where as its distance from 52-week high of $4.37 is -0.85%.
How many employees does NKTR have?
Number of NKTR employees currently stands at N/A. NKTR operates from 455 Mission Bay Boulevard South, San Francisco, CA 94158, US.
Link for NKTR official website?
Official Website of NKTR is: https://www.nektar.com
How do I contact NKTR?
NKTR could be contacted at phone #415 482 5300 and can also be accessed through its website. NKTR operates from 455 Mission Bay Boulevard South, San Francisco, CA 94158, US.
How many shares of NKTR are traded daily?
NKTR stock volume for the day was 1128104.00 shares. The average number of NKTR shares traded daily for last 3 months was 1.67 Million.
What is the market cap of NKTR currently?
The market value of NKTR currently stands at $100.15 Million with its latest stock price at $0.53 and N/A of its shares outstanding.